CDKL5 Deficiency Disorder Market to Witness Upsurge in Growth, Assesses DelveInsight | Key Companies in the Market - Jazz, Stoke, Epygenix, Zogenix, UCB Pharma, Takeda, Eisai, Longboard, Marinus
The dynamics of the CDKL5 deficiency disorder market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the diseases, incremental healthcare spending across the world, and also expects the launch of emerging therapies during the forecast period of 2023–2032.
LAS VEGAS, June 6, 2023 /PRNewswire/ -- DelveInsight's CDKL5 Deficiency Disorder Market Insights report includes a comprehensive understanding of current treatment practices, CDKL5 deficiency disorder emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the CDKL5 Deficiency Disorder Market Report
- As per DelveInsight analysis, the CDKL5 deficiency disorder market is expected to grow positively at a significant CAGR during the study period (2019–2032).
- According to the International Foundation for CDKL5 Research, although rare, the occurrence is believed to be ~1:40,000-60,000 live births, making it one of the most common forms of genetic epilepsy.
- Globally, leading CDKL5 deficiency disorder companies such as Jazz Pharmaceuticals, Stoke Therapeutics, Inc, Epygenix, Zogenix, Inc., UCB Pharma, Takeda, Eisai Inc., Longboard Pharmaceuticals, Marinus Pharmaceuticals, Ultragenyx Pharmaceutical, Amicus Therapeutics, Ovid Therapeutics, REGENXBIO, and others are developing novel CDKL5 deficiency disorder drugs that can be available in the CDKL5 deficiency disorder market in the coming years.
- Some key therapies for CDKL5 deficiency disorder treatment include GWP42003-P, STK-001, EPX-100, ZX008, Soticlestat, Lorcaserin, LP352, Ganaxolone, and others.
Discover which therapies are expected to grab the major CDKL5 deficiency disorder market share @ CDKL5 Deficiency Disorder Market Report
CDKL5 Deficiency Disorder Overview
CDKL5 deficiency disorder is a rare form of developmental epileptic encephalopathy (DEE) caused by alterations in the CDKL5 gene. CDD has been designated as a DEE since the genetic mutation produces both epileptic activity and significant developmental disability. CDKL5, also known as serine/threonine-protein kinase 9 (STK9), was initially discovered as a disease-causing gene in 2004. The most common CDKL5 deficiency disorder symptoms are epileptic seizures that begin early in life, epileptic spasms that frequently occur without hypsarrhythmia, multiple types of seizures, limited ability to walk, limited hand skills, lack of eye contact, constipation, sleep difficulties, intellectual disability, and so on. Clinical presentation is used to make the CDKL5 deficiency disorder diagnosis, which is then validated by molecular genetic testing for CDKL5 mutations or multigene panel testing for early-onset epilepsy.